[Clonidine treatment in manic episodes].

Area of Science:

• Psychiatry
• Pharmacology

Background:

• Acute manic disorders present significant treatment challenges.
• Current therapies, like neuroleptics, can have substantial side effects, including over-sedation.
• Clonidine, an alpha-2-adrenergic agonist, is primarily known for its antihypertensive properties.

Purpose of the Study:

• To evaluate the efficacy and safety of clonidine in treating acute manic disorders.
• To assess the speed of onset and duration of clonidine's therapeutic effects.
• To compare the side effect profile of clonidine with traditional neuroleptics.

Main Methods:

• A clinical study involving 20 hospitalized patients with acute manic disorders.
• Daily administration of clonidine at doses ranging from 450-750 micrograms for one month.
• Monitoring of manic symptoms, patient tolerance, and adverse effects.

Main Results:

• Excellent tolerance to clonidine was observed in all patients.
• A significant decrease in manic symptoms was noted in 65% of patients within ten days.
• Clonidine demonstrated rapid efficacy across all manic syndrome symptoms, with sustained effects throughout the study.
• The supra-sedation effect was considerably lower compared to neuroleptics.

Conclusions:

• Clonidine is an effective and well-tolerated treatment for acute manic disorders.
• Its rapid onset, sustained efficacy, and favorable side effect profile, particularly reduced sedation, represent a practical advancement in acute manic episode management.
• Further research into clonidine's mechanism in treating mania is warranted.